Organism: Homo sapiens
Gene: 39187_at
Selected probe(set): 232231_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39187_at (232231_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-7.33055
Number of Samples:7 / 3

Experimental	Langerhans cell histiocytosis study 1
	Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control	normal plasmocytoid dendritic cell sample
	Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

Relative Expression (log2-ratio):-6.583708
Number of Samples:6 / 5

Experimental	precursor-B-ALL study 3 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-6.551469
Number of Samples:15 / 5

Experimental	precursor-B-ALL study 3 (TEL-AML1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-6.4804573
Number of Samples:6 / 5

Experimental	precursor-B-ALL study 3 (PAX5-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-6.445198
Number of Samples:4 / 4

Experimental	OPM-1
	Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control	MM1.S
	Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

Relative Expression (log2-ratio):6.155463
Number of Samples:3 / 3

Experimental	dexamethasone study 9 (24h)
	CCRF-CEM-C7H2 cells cultured in the presence of dexamethansone (10e-7M) for 24 hours. ATC code:, , , , , , , , , ,
Control	EtOH treated CCRF-CEM-C7H2 cell sample
	CCRF-CEM-C7H2 cells treated for 24 hours with 0.1% ethanol (EtOH) as carrier control.

Relative Expression (log2-ratio):-5.9621735
Number of Samples:17 / 5

Experimental	precursor-B-ALL study 3 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):5.5020094
Number of Samples:4 / 21

Experimental	precursor-B-ALL study 2 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (TEL-AML1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):5.442808
Number of Samples:5 / 22

Experimental	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (unspecified)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (no specific subtype). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-5.349118
Number of Samples:6 / 3

Experimental	RAF1 depletion study 1
	RNAi-mediated gene knockdown of RAF1 in colorectal cancer cell line SW-480.
Control	normal SW-480 cell sample
	Non-transduced SW-480 colorectal cell line sample.